As part of its $15 billion investment in China, the drugmaker intends to become the first global biopharma company with end-to-end cell therapy capabilities in the country.
Chinese production of active pharmaceutical ingredients and key starting materials is putting Americans at risk, according to a bipartisan congressional committee.
The new biomanufacturing campus in Holly Springs, North Carolina was modelled after a large-scale production site in Hillerød, Denmark, cutting design time by 70%.
Guidance reflects customer loss due to change in its supply strategy, lower hyaluronic acid revenue from customer, and delayed customer launch that was slated for this year.
The agency cited the CDMO’s significant violations of current Good Manufacturing Practice regulations for finished pharmaceuticals at Simtra’s Halle/Westfalen facility.
These therapies are poised to reshape treatment standards this year, from next‑gen metabolic drugs to breakthrough advances in oncology, immunology, and rare diseases.
The 125,000-square-foot facility, which is slated to be operational in 2027, is where cutting-edge genetic medicine will meet industrial scale, says CEO Chris Murphy.
The agency issued a Complete Response Letter for Incyte’s supplemental Biologics License Application, citing inspection findings at Novo Nordisk’s fill-finish facility.
The divestment of the business to Lone Star Funds enables Lonza’s transformation to become a pure-play contract development and manufacturing organization.
Big Pharma and contract development and manufacturing organizations are making large capital expenditures to build infrastructure supporting the wildly popular medications.
Ongoing investments in its Fishers, Indiana and Latina, Italy sites are expanding capacity for high-value products, while the company pivots away from other categories.
Lilly is struggling to find the talent required for these capital expenditure projects, says Steve Marr, head of the drugmaker’s global facilities delivery parenteral.
Home to pharma giants Roche and Novartis, the Swiss city along the Rhine River is attracting biotech companies of all sizes that are driving life sciences innovation.
With the launch of the Wegovy pill in the U.S., the drugmaker is adding manufacturing capacity to its Athlone, Ireland site to support current and future GLP-1 treatments.
Chris Chen, CEO of WuXi Biologics, discusses his organization’s approach to ensuring consistent quality, reliability, and speed of biologics development and manufacturing.
Overall, the company’s specialty CDMO business grew in the low-double digits during the first quarter of fiscal 2026, with expectations of mid-teens growth this year.
The company is selling contract development and manufacturing organization sites in Tennessee, Maryland, and the UK, as well as a cell solutions site in California.
Of about $600 billion in domestic investments announced in 2025, only $60 billion worth of estimated capital expenditures have specific amounts and locations, finds CBRE.
Since SK bioscience acquired a 60% stake in the CDMO, the company has undertaken a “full-scale drive” to expand its business in vaccines and biopharmaceuticals.
The CDMO’s “conservative” guidance is due to limited visibility around a pending customer confirmation for a large contract that could impact sales growth this year.
Despite the legal setback for President Trump’s country-specific tariffs, he retains the authority to impose Section 232 tariffs on pharmaceuticals imported to the U.S.
To counter the Chinese government’s investment, the U.S. must make a coordinated effort to grow biomanufacturing base, argues a bipartisan commission created by Congress.
The CDMO has strengthened its oral solid dose and antibody-drug conjugate capabilities as drugmakers diversify away from China and expand onshore production.
Organic revenue for the company’s manufacturing solutions decreased 2.1%, driven by lower revenue in its contract development and manufacturing organization segment.
As artificial intelligence tools proliferate, the real challenge is not generating ideas but turning them into chemically feasible and manufacturable paths.
The pharma giant has added to its inventory of orforglipron in anticipation of a favorable regulatory decision by the U.S. Food and Drug Administration.